Can aprepitant used for nausea and vomiting be good gastrointestinal complaints?
| Autor: | Duygu Kose, Muhammed Yayla, Zekai Halici, Tugba Bal Tastan, Rustem Anil Ugan, Harun Un, Elif Cadirci |
|---|---|
| Přispěvatelé: | Belirlenecek |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine System medicine.medical_treatment Gastroenterology 0302 clinical medicine Omeprazole Aprepitant Cancer Stomach Nausea General Medicine Receptor antagonist medicine.anatomical_structure 030220 oncology & carcinogenesis Vomiting Gastric Hyperemia Inflammation Mediators medicine.symptom medicine.drug Receptor medicine.medical_specialty medicine.drug_class 03 medical and health sciences Internal medicine Tachykinins medicine Acid Animals Stomach Ulcer Rats Wistar Ulcer Secretion Pharmacology Chemotherapy business.industry Cyclooxygenase-2 Expression medicine.disease Rats 030104 developmental biology Gastric Mucosa Localization Substance-P Antiemetics Rat Gastrointestinal complaints business |
| Popis: | Aprepitant is a selective SP/NK-1 receptor antagonist and used in postoperative and chemotherapeutics induced emesis and vomiting. The aim of our study is to show aprepitant may have beneficial effects on gastrointestinal complaints in cancer patients undergoing chemotherapeutics by indomethacin-induced gastric ulcer model. A total of 48 rats were fasted 24 h for ulcer experiment. Aprepitant doses of 5, 10, 20, and 40 mg/kg were evaluated for their antiulcer activity. Omeprazole (20 mg/kg) was used as a positive control group. Six hours after 25 mg/kg indomethacin administration, all stomachs were dissected out. After macroscopic analyses, tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), COX-1, and COX-2 mRNA levels and SOD activity, and GSH and MDA levels of stomachs were determined. Histopathological examinations were evaluated. Aprepitant administration exerted 48.14%, 49.62%, 65.92%, and 76.77% ulcer inhibition effects at 5, 10, 20, and 40 mg/kg, respectively. Aprepitant administration decreased oxidative stress and inflammatory parameters in stomach tissues dose dependently. Aprepitant administration increased stomach COX-2 mRNA levels at 20 and 40 mg/kg doses. Although aprepitant appears to be disadvantageous in terms of treating gastric ulcer due to COX enzyme inhibition according to the previous studies, aprepitant has been shown to have ulcer healing effect in our study. When aprepitant is given as an anti-nausea and vomiting drug to cancer patients undergoing chemotherapy, we can argue that it will not be necessary to add a new gastric protective agent as it also shows beneficial effects in gastrointestinal complaints. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|